Handelsbanken Fonder Ab Hutchmed (China) LTD Transaction History

Handelsbanken Fonder Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$28.89 - $35.33 $494,019 - $604,143	-17,100 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$23.7 - $39.27 $118,500 - $196,350	5,000 Added 41.32%	17,100 $672,000
Q3 2020 Nov 13, 2020	BUY	$25.8 - $34.61 $92,880 - $124,596	3,600 Added 42.35%	12,100 $391,000
Q2 2020 Aug 13, 2020	BUY	$17.65 - $28.05 $150,025 - $238,425	8,500 New	8,500 $234,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.